The Genetics of Parkinson's Diseases

A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Neurodegenerative Diseases".

Deadline for manuscript submissions: closed (30 December 2023) | Viewed by 2247

Special Issue Editor


E-Mail Website
Guest Editor
Faculty of Medicine Sciences, University of Santiago, Santiago, Chile
Interests: Parkinson's disease; movement disorders; genetic

Special Issue Information

Dear Colleagues,

Parkinson's disease is a neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra that project to the striatum. From the genetic point of view, it is a complex multifactorial disease in which genetic and environmental factors overlap.

Familial cases that respond to specific mutations are infrequent; another group of genes confers a risk of developing the disease forms of expression. However, the vast majority are sporadic without a specific associated gene, understanding that they act in a polygenic risk manner. It is in this group that most of the research has been concentrated in recent times.

The dominant, autosomal expression forms are SNCA, LRRK2, VPS35 and autosomal recessive expression forms such as PARK, DJ1, PINK1, ATP13A2; it should be considered that the central axis is the phenotype of parkinsonism, however, varies in terms of the frequency of association with other cognitive, dysautonomic or other symptoms and its presentation in time.

The aim to the Special Issue is to collect the articles about Parkinson's disease and genetics, and introduce recent findings.

Prof. Dr. Pedro Chaná-Cuevas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • parkinsonism
  • Parkinson disease
  • genetics
  • phenotype
  • movement disorders

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 3444 KiB  
Article
mTORC1-Dependent Protein and Parkinson’s Disease: A Mendelian Randomization Study
by Cheng Tan, Jianzhong Ai and Ye Zhu
Brain Sci. 2023, 13(4), 536; https://doi.org/10.3390/brainsci13040536 - 24 Mar 2023
Cited by 3 | Viewed by 1865
Abstract
Background: The mTOR pathway is crucial in controlling the growth, differentiation, and survival of neurons, and its pharmacological targeting has promising potential as a treatment for Parkinson’s disease. However, the function of mTORC1 downstream proteins, such as RPS6K, EIF4EBP, EIF-4E, EIF-4G, and EIF4A, [...] Read more.
Background: The mTOR pathway is crucial in controlling the growth, differentiation, and survival of neurons, and its pharmacological targeting has promising potential as a treatment for Parkinson’s disease. However, the function of mTORC1 downstream proteins, such as RPS6K, EIF4EBP, EIF-4E, EIF-4G, and EIF4A, in PD development remains unclear. Methods: We performed a Mendelian randomization study to evaluate the causal relationship between mTORC1 downstream proteins and Parkinson’s disease. We utilized various MR methods, including inverse-variance-weighted, weighted median, MR–Egger, MR-PRESSO, and MR-RAPS, and conducted sensitivity analyses to identify potential pleiotropy and heterogeneity. Results: The genetic proxy EIF4EBP was found to be inversely related to PD risk (OR = 0.79, 95% CI = 0.67–0.92, p = 0.003), with the results from WM, MR-PRESSO, and MR-RAPS being consistent. The plasma protein levels of EIF4G were also observed to show a suggestive protective effect on PD (OR = 0.85, 95% CI = 0.75–0.97, p = 0.014). No clear causal effect was found for the genetically predicted RP-S6K, EIF-4E, and EIF-4A on PD risk. Sensitivity analyses showed no significant imbalanced pleiotropy or heterogeneity, indicating that the MR estimates were robust and independent. Conclusion: Our unbiased MR study highlights the protective role of serum EIF4EBP levels in PD, suggesting that the pharmacological activation of EIF4EBP activity could be a promising treatment option for PD. Full article
(This article belongs to the Special Issue The Genetics of Parkinson's Diseases)
Show Figures

Figure 1

Back to TopTop